PULMATRIX, INC. Increase (Decrease) in Other Noncurrent Assets
PULMATRIX, INC. (PULM) reported Increase (Decrease) in Other Noncurrent Assets of -$13.00 thousand for the 12-month period ending 2025-12-31, per its S-4/A filed 2026-09-17.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherNoncurrentAssets · last filed 2026-09-17
- PULMATRIX, INC. increase (decrease) in other noncurrent assets for the quarter ending 2025-12-31 was $0.00.
- PULMATRIX, INC. increase (decrease) in other noncurrent assets for the quarter ending 2025-09-30 was $0.00.
- PULMATRIX, INC. increase (decrease) in other noncurrent assets for the quarter ending 2025-06-30 was $0.00.
- PULMATRIX, INC. increase (decrease) in other noncurrent assets for the quarter ending 2025-03-31 was -$13.00K.
- PULMATRIX, INC. increase (decrease) in other noncurrent assets for fiscal 2023 was -$213.00K, a 154.76% decline from fiscal 2022.
- PULMATRIX, INC. increase (decrease) in other noncurrent assets for fiscal 2022 was $389.00K.
| Period end | Increase (Decrease) in Other Noncurrent Assets 3 month | Increase (Decrease) in Other Noncurrent Assets 6 month | Increase (Decrease) in Other Noncurrent Assets 9 month | Increase (Decrease) in Other Noncurrent Assets 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: S-4/A 12 month − 10-Q 9 month · filed 2026-09-17 | $0.00 derived: sum of 2 quarters · filed 2026-09-17 | $0.00 derived: sum of 3 quarters · filed 2026-09-17 | -$13.00K S-4/A · filed 2026-09-17 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − S-4/A 6 month · filed 2025-10-16 | $0.00 derived: sum of 2 quarters · filed 2026-09-17 | -$13.00K 10-Q · filed 2025-10-16 | -$54.00K derived: sum of 4 quarters · filed 2026-09-17 |
| 2025-06-30 | $0.00 derived: S-4/A 6 month − S-4/A 3 month · filed 2026-09-17 | -$13.00K S-4/A · filed 2026-09-17 | -$54.00K derived: sum of 3 quarters · filed 2026-09-17 | -$93.00K derived: sum of 4 quarters · filed 2026-09-17 |
| 2025-03-31 | -$13.00K S-4/A · filed 2026-08-03 | -$54.00K derived: sum of 2 quarters · filed 2026-09-17 | -$93.00K derived: sum of 3 quarters · filed 2026-09-17 | -$135.00K derived: sum of 4 quarters · filed 2026-09-17 |
| 2024-12-31 | -$41.00K derived: S-4/A 12 month − 10-Q 9 month · filed 2026-09-17 | -$80.00K derived: sum of 2 quarters · filed 2026-09-17 | -$122.00K derived: sum of 3 quarters · filed 2026-09-17 | -$163.00K S-4/A · filed 2026-09-17 |
| 2024-09-30 | -$39.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-16 | -$81.00K derived: sum of 2 quarters · filed 2025-10-16 | -$122.00K 10-Q · filed 2025-10-16 | -$163.00K derived: sum of 4 quarters · filed 2025-10-16 |
| 2024-06-30 | -$42.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$83.00K 10-Q · filed 2025-08-06 | -$124.00K derived: sum of 3 quarters · filed 2025-08-06 | -$1.89M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | -$41.00K 10-Q · filed 2025-05-15 | -$82.00K derived: sum of 2 quarters · filed 2025-05-15 | -$1.85M derived: sum of 3 quarters · filed 2025-05-15 | -$764.00K derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | -$41.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-21 | -$1.81M derived: sum of 2 quarters · filed 2025-03-21 | -$723.00K derived: sum of 3 quarters · filed 2025-03-21 | -$213.00K 10-K · filed 2025-03-21 |
| 2023-09-30 | -$1.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | -$682.00K derived: sum of 2 quarters · filed 2024-11-08 | -$172.00K 10-Q · filed 2024-11-08 | -$211.00K derived: sum of 4 quarters · filed 2024-11-08 |
| 2023-06-30 | $1.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $1.59M 10-Q · filed 2024-08-13 | $1.56M derived: sum of 3 quarters · filed 2024-08-13 | $1.62M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $510.00K 10-Q · filed 2024-05-10 | $471.00K derived: sum of 2 quarters · filed 2024-05-10 | $531.00K derived: sum of 3 quarters · filed 2024-05-10 | |
| 2022-12-31 | -$39.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $21.00K derived: sum of 2 quarters · filed 2024-03-28 | $389.00K 10-K · filed 2024-03-28 | |
| 2022-09-30 | $60.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $428.00K 10-Q · filed 2023-11-09 | ||
| 2022-06-30 | $368.00K 10-Q · filed 2023-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |